Resultado de búsqueda
4 de jun. de 2023 · In a single-center pilot trial of neoadjuvant FOLFOX in which administration of chemoradiotherapy was reserved for patients whose tumors did not respond to chemotherapy, we found favorable ...
7 de jun. de 2023 · It improves disease-free survival (DFS) by decreasing pelvic recurrence but has short- and long-term toxicity. The PROSPECT trial compares FOLFOX chemotherapy with selective use of 5FUCRT (intervention) to 5FUCRT (control) for neoadjuvant treatment prior to TME for LARC.
27 de jul. de 2023 · In patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival. (Funded by the National Cancer Institute; PROSPECT ClinicalTrials.gov number, NCT01515787.).
4 de jun. de 2023 · Data from the randomized phase 3 noninferiority PROSPECT trial, presented during the ASCO Annual Meeting Plenary Session, showed that neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) was noninferior to 5-FU CRT in participants with locally advanced rectal cancer (LBA2).
25 de oct. de 2023 · To the Editor: I congratulate Schrag et al. (July 27 issue) 1 for successful completion of the PROSPECT trial (Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with...
4 de jun. de 2023 · PROSPECT was a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX versus 5FUCRT, which enrolled adults with rectal cancer clinically staged as T2N+, cT3N–, or cT3N+ who were candidates for sphincter-sparing surgery.
The PROSPECT trial (N1048, NCT01515787) was designed to determine whether neoadjuvant chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX) could be used as an alternative to neoadjuvant chemoradiation without compromising treatment outcomes and to spare these patients excess toxicity.